199 related articles for article (PubMed ID: 23468975)
1. Clinical and biological relevance of genomic heterogeneity in chronic lymphocytic leukemia.
Friedman DR; Lucas JE; Weinberg JB
PLoS One; 2013; 8(2):e57356. PubMed ID: 23468975
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
Rodríguez-Vicente AE; Díaz MG; Hernández-Rivas JM
Cancer Genet; 2013 Mar; 206(3):49-62. PubMed ID: 23531595
[TBL] [Abstract][Full Text] [Related]
3. Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.
Seiffert M; Dietrich S; Jethwa A; Glimm H; Lichter P; Zenz T
Leuk Lymphoma; 2012 Jun; 53(6):1023-31. PubMed ID: 22023519
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia.
Ouillette P; Collins R; Shakhan S; Li J; Li C; Shedden K; Malek SN
Clin Cancer Res; 2011 Nov; 17(21):6778-90. PubMed ID: 21890456
[TBL] [Abstract][Full Text] [Related]
5. Genetic features of B-cell chronic lymphocytic leukemia.
Stilgenbauer S; Lichter P; Döhner H
Rev Clin Exp Hematol; 2000 Mar; 4(1):48-72. PubMed ID: 11486330
[TBL] [Abstract][Full Text] [Related]
6. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
[TBL] [Abstract][Full Text] [Related]
7. Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia.
Winkler D; Döhner H; Stilgenbauer S
Curr Drug Targets; 2006 Oct; 7(10):1313-27. PubMed ID: 17073593
[TBL] [Abstract][Full Text] [Related]
8. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.
Ouillette P; Erba H; Kujawski L; Kaminski M; Shedden K; Malek SN
Cancer Res; 2008 Feb; 68(4):1012-21. PubMed ID: 18281475
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling.
Rodríguez AE; Robledo C; García JL; González M; Gutiérrez NC; Hernández JA; Sandoval V; García de Coca A; Recio I; Risueño A; Martín-Núñez G; García E; Fisac R; Conde J; de Las Rivas J; Hernández JM
Ann Oncol; 2012 Aug; 23(8):2138-2146. PubMed ID: 22228453
[TBL] [Abstract][Full Text] [Related]
10. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
Ouillette P; Saiya-Cork K; Seymour E; Li C; Shedden K; Malek SN
Clin Cancer Res; 2013 Jun; 19(11):2893-904. PubMed ID: 23620403
[TBL] [Abstract][Full Text] [Related]
11. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status.
Haslinger C; Schweifer N; Stilgenbauer S; Döhner H; Lichter P; Kraut N; Stratowa C; Abseher R
J Clin Oncol; 2004 Oct; 22(19):3937-49. PubMed ID: 15459216
[TBL] [Abstract][Full Text] [Related]
12. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.
Malek SN
Oncogene; 2013 Jun; 32(23):2805-17. PubMed ID: 23001040
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
14. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation.
Rodríguez A; Villuendas R; Yáñez L; Gómez ME; Díaz R; Pollán M; Hernández N; de la Cueva P; Marín MC; Swat A; Ruiz E; Cuadrado MA; Conde E; Lombardía L; Cifuentes F; Gonzalez M; García-Marco JA; Piris MA;
Leukemia; 2007 Sep; 21(9):1984-91. PubMed ID: 17611561
[TBL] [Abstract][Full Text] [Related]
15. Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells.
Eagle GL; Herbert JMJ; Zhuang J; Oates M; Khan UT; Kitteringham NR; Clarke K; Park BK; Pettitt AR; Jenkins RE; Falciani F
Sci Rep; 2021 Feb; 11(1):2932. PubMed ID: 33536534
[TBL] [Abstract][Full Text] [Related]
16. Evolving understanding of the CLL genome.
Gruber M; Wu CJ
Semin Hematol; 2014 Jul; 51(3):177-87. PubMed ID: 25048782
[TBL] [Abstract][Full Text] [Related]
17. The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia.
Amiel A; Leopold L; Gronich N; Yukla M; Fejgin MD; Lishner M
Cancer Genet Cytogenet; 2006 Jun; 167(2):145-9. PubMed ID: 16737914
[TBL] [Abstract][Full Text] [Related]
18. RNA-based markers as prognostic factors in chronic lymphocytic leukemia.
Sevov M; Rosenquist R; Mansouri L
Expert Rev Hematol; 2012 Feb; 5(1):69-79. PubMed ID: 22272707
[TBL] [Abstract][Full Text] [Related]
19. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.
Ouillette P; Fossum S; Parkin B; Ding L; Bockenstedt P; Al-Zoubi A; Shedden K; Malek SN
Clin Cancer Res; 2010 Feb; 16(3):835-47. PubMed ID: 20086003
[TBL] [Abstract][Full Text] [Related]
20. Chronic lymphocytic leukemia.
Byrd JC; Stilgenbauer S; Flinn IW
Hematology Am Soc Hematol Educ Program; 2004; ():163-83. PubMed ID: 15561682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
